Lytix Biopharma Appoints Timothy Herpin as Chief Business Officer
Clinical-stage immuno-oncology company Lytix Biopharma ASA announced the appointment of Timothy F. Herpin as Chief Business Officer. The appointment aims to enhance the company's global business development and partnering capabilities.
Oslo, Norway – Lytix Biopharma ASA, a clinical-stage immuno-oncology company, announced today the appointment of Timothy F. Herpin, Ph.D., M.B.A., as Chief Business Officer. Herpin will begin his role on a fractional basis effective August 17, 2026.
The appointment is intended to bolster the company's global business development and partnering efforts. Lytix Biopharma is advancing its clinical programs and is actively seeking strategic partnerships across its portfolio.
Herpin brings more than 25 years of experience in the pharmaceutical and biotechnology sectors. His background includes significant expertise in mergers and acquisitions, licensing, and strategic planning, with prior leadership roles at several pharmaceutical companies.
Lytix Biopharma is focused on developing novel intratumoral cancer therapies. The company's objective is to improve cancer treatment by offering more effective and targeted therapeutic options for patients.